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  Surgery of long bone metastases is associated with a sig-
nificant risk of perioperative blood loss, which may neces-
sitate blood transfusion.
  Successful embolization (> 70% obliteration of vascularity) 
can be achieved in 36–75% of cases.
  The reported rate of embolization-related complications is 
0–9%.
  Three out of six level III evidence studies showed a reduc-
tion in perioperative blood loss and/or blood transfusion 
requirement after preoperative embolization of renal cell 
carcinoma metastasis in long bones; three out of six stud-
ies did not.
  One level III evidence study did not show a reduction in 
perioperative blood loss and/or transfusion requirement 
after preoperative embolization of hepatocellular carci-
noma metastases in long bones.
  There were no studies found that support preoperative 
embolization of thyroid metastases or other frequent long 
bone metastases (e.g. mamma carcinoma, lung carci-
noma, or prostate carcinoma).
  The clinical level of evidence of the studies found is low 
and randomized studies taking into account primary 
tumour, location of metastases and type of surgery are 
therefore desired.
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Introduction
Due to constantly improving treatments that prolong the 
palliative phase of many different cancers, the incidence 
of bone metastases is increasing.1 Nowadays, over two-
thirds of patients receiving palliative care will develop 
bone metastases.2,3 These bone metastases cause clinical 
symptoms that require treatment in more than half of 
these patients.4 Clinical symptoms occurring due to long 
bone metastases include pain, with 10–25% of patients 
presenting with impending or actual pathological frac-
tures.5 Those impending or actual pathological fractures 
regularly require surgical treatment in order to prevent or 
stabilize fractures.
Surgical procedures used to stabilize impending or 
actual fractures vary from minimally invasive procedures 
such as intramedullary nailing, to extensive open proce-
dures such as joint replacement. These surgical proce-
dures in themselves can result in significant perioperative 
blood loss, which might be increased due to the hyper-
vascularity of certain bone metastases.6 Even minimally 
invasive intramedullary stabilization of femoral bone 
metastases has been shown to require transfusion of 2.5 
units of allogeneic blood due to blood loss.7 This periop-
erative blood loss may lead to longer surgery times and 
might increase the risk of intraoperative mortality, which 
is estimated to be around 0.6–1.0% in surgically treated 
femoral bone metastases.8 The need for allogenic blood 
transfusions has also been shown to negatively affect 
long-term survival in patients with surgically treated long 
bone metastases. The risk of mortality is increased by 7% 
per unit of transfused blood.9 Furthermore, blood transfu-
sions are generally associated with an increased risk of 
developing postoperative infections.10 Postoperative 
infection rates of 0–15% are reported for surgically treated 
femoral bone metastases, and are more frequently seen 
after placement of tumour prostheses.11
Preoperative embolization, prior to (impending) frac-
ture stabilization is used to reduce perioperative blood 
loss. Preoperative embolization of metastases was origi-
nally described for hypervascular tumours such as renal 
cell carcinoma and thyroid carcinoma.6,12 However, there 
is no consensus in the guidelines or literature as to which 
types of long bone metastasis benefit from preoperative 
embolization in order to reduce blood loss. The primary 
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aim of this systematic review was to identify long bone 
metastases that benefit from preoperative embolization in 
order to reduce perioperative blood loss or blood transfu-
sion requirement. Therefore, we determined the effective-
ness of embolization, the incidence of embolization-related 
complications, reduction in operation time and optimal 
timing of surgery following embolization.
Methods
Search strategy and eligibility criteria
The Preferred Reporting Items for Systematic reviews and 
Meta-Analyses (PRISMA) guidelines were used as a guide 
for planning and performing this systematic review.13 We 
conducted a systematic review of the literature to retrieve 
all clinical studies listed in PubMed, Embase, Medline, 
Web of science, Cochrane and Google scholar (1998 to 
December 2017) containing information on blood loss 
and/or transfusion rate of patients with preoperative 
embolization prior to surgical treatment of long bone 
metastases. Our search was performed on 1 December 
2017 and was refreshed on 20 December 2018. Search 
terms were categorized to retrieve all studies concerning 
embolization and bone metastases. The complete search 
is provided in Table 1. First, all retrieved titles were com-
bined in Endnote (X7.5), then duplicate articles were 
removed and all titles and abstract were screened by two 
independent authors (SG and JS) to select eligible articles. 
Then full-text articles were read and included or excluded 
based on the exclusion and inclusion criteria given in 
Table 2. Any discrepancy between the authors was 
resolved through discussion. All the reference lists of the 
full-text articles were screened for relevant articles that 
had not been found through the literature search.
Analysis of data
The primary outcome measure is reduction in periopera-
tive blood loss, which can be measured directly as periop-
erative blood loss or indirectly through decrease in 
haemoglobin or the need for blood transfusion. Secondary 
outcome measures were: operation time and embolization- 
related complications, as well as timing between preop-
erative embolization and surgery. Furthermore, data on 
patient characteristics (age, sex, number), primary 
tumour, location, timing of embolization, type of surgery, 
study design, perioperative blood loss, and transfusion 
requirement were collected for each study. To assess for 
risk of bias of the included studies, the Methodological 
Index for Non-Randomized Studies (MINORS) was used.14 
To assess the level of evidence, the Oxford Centre for Evi-
dence Based Medicine table (OCEBM) was assigned to 
Table 1. Complete search
embase.com 854
('artificial embolization'/exp OR (embolization* OR embolisation* OR embolized OR embolised OR chemoemboli* OR radioemboli* OR ((artificial* OR 
transcatheter* OR catheter* OR chemo* OR radio* OR transarter* OR therapeut*) NEAR/6 (embol* OR thrombus*)) OR embolotherap* OR (therapeut* NEAR/3 
occlusi*) OR tace OR tare OR tae):ab,ti) AND ('bone metastasis'/exp OR 'bone marrow metastasis'/de OR 'spine metastasis'/de OR ('bone'/exp AND metastasis/
de) OR (((bone OR bones OR osseous OR osteoplast* OR skelet* OR musculoskelet* OR spine OR spinal OR pelvis OR pelvic OR vertebra* OR femur OR femoral 
OR humer* OR tibia* OR costal) NEAR/6 metastas*)):ab,ti) NOT ([animals]/lim NOT [humans]/lim) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim 
OR [Editorial]/lim)
Medline Ovid 346
(Embolization, Therapeutic/ OR Chemoembolization, Therapeutic/ OR (embolization* OR embolisation* OR embolized OR embolised OR chemoemboli* 
OR radioemboli* OR ((artificial* OR transcatheter* OR catheter* OR chemo* OR radio* OR transarter* OR therapeut*) ADJ6 (embol* OR thrombus*)) OR 
embolotherap* OR (therapeut* ADJ3 occlusi*) OR tace OR tare OR tae).ab,ti.) AND ((exp Bone and Bones/ AND Neoplasm Metastasis/) OR (((bone OR bones OR 
osseous OR osteoplast* OR skelet* OR musculoskelet* OR spine OR spinal OR pelvis OR pelvic OR vertebra* OR femur OR femoral OR humer* OR tibia* OR costal) 
ADJ6 metastas*)).ab,ti.) NOT (exp animals/ NOT humans/) NOT (letter OR news OR comment OR editorial OR congresses OR abstracts).pt.
Cochrane CENTRAL 12
((embolization* OR embolisation* OR embolized OR embolised OR chemoemboli* OR radioemboli* OR ((artificial* OR transcatheter* OR catheter* OR chemo* 
OR radio* OR transarter* OR therapeut*) NEAR/6 (embol* OR thrombus*)) OR embolotherap* OR (therapeut* NEAR/3 occlusi*) OR tace OR tare OR tae):ab,ti) 
AND ((((bone OR bones OR osseous OR osteoplast* OR skelet* OR musculoskelet* OR spine OR spinal OR pelvis OR pelvic OR vertebra* OR femur OR femoral OR 
humer* OR tibia* OR costal) NEAR/6 metastas*)):ab,ti)
Web of science 278
TS=(((embolization* OR embolisation* OR embolized OR embolised OR chemoemboli* OR radioemboli* OR ((artificial* OR transcatheter* OR catheter* OR 
chemo* OR radio* OR transarter* OR therapeut*) NEAR/5 (embol* OR thrombus*)) OR embolotherap* OR (therapeut* NEAR/2 occlusi*) OR tace OR tare OR tae)) 
AND ((((bone OR bones OR osseous OR osteoplast* OR skelet* OR musculoskelet* OR spine OR spinal OR pelvis OR pelvic OR vertebra* OR femur OR femoral OR 
humer* OR tibia* OR costal) NEAR/5 metastas*))) ) AND DT=(article)
Google scholar 200
embolization|embolisation|chemoembolization|"artificial|transcatheter|therapeutic embolism|thrombus"  
"bone|bones|osseous|osteoplastic|skeletal|musculoskeletal|spine|spinal|pelvis|pelvic|vertebral|femur|femoral|humerus|humeral|tibia|tibial metastasis|metastases"
Table 2. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Long bone metastases with preoperative 
embolization
< 5 eligible patients
Given outcome variable (blood loss and/or 
transfusion rate)
Spinal and skull metastases
Known primary tumour Technical descriptive studies
Control group Primary osseous malignancy
Detailed treatment and outcome 
information
Vascular malformations
Original publications in English, German 
or Dutch language
 
Publication date between 1988 and 2018  
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each study (OCEBM Levels of Evidence Working Group, 
‘The Oxford Levels of Evidence 2’).
Results
Literature search
The search process of our systematic review is presented 
in the PRISMA flow chart (Fig. 1). Our initial search 
retrieved a total of 1690 studies of which, after exclusion 
of duplicate studies, 1098 studies where further screened 
by two independent reviewers (SG and JS). In total, 61 
studies were considered eligible based on title and 
abstract. After reading the full-text articles of those 61 eli-
gible studies, another 54 articles were excluded due to the 
following exclusion criteria: spinal or pelvic metastases 
only (n = 39); reports with < 5 eligible cases (n = 7);15–21 
review article (n = 2);22,23 incomplete outcome data given 
(n = 4);6,24–26 short practical instruction article (n = 1);27 
lack of a control group (n = 1).28 This led to a final number 
of seven articles that met all inclusion criteria.29–35 A risk of 
bias analysis was performed for each of those seven stud-
ies (Table 3). Reference screening of the full-text articles 
did not yield additional references.
Risk of bias and level of evidence
No randomized controlled trials were found, the seven 
articles that were included all were retrospective case-
cohort studies, providing an OCEBM score of 3. The 
MINORS scores ranged from 7 to 13 (Table 3).
Primary outcome measures
The primary outcome measures are summarized in 
Table 4.
Blood loss in metastasis of renal cell carcinoma
Six studies compared the effect of preoperative emboliza-
tion of renal cell metastases to a control group. Of those 
six studies, three reported a significant reduction in perio-
perative blood loss and/or blood transfusion requirement. 
Three studies (Pazionis et  al,32 Ratasvuori et  al33 and 
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Additional records identified
through other sources
(n = 0)
Records after duplicates removed
(n = 1098)
Records screened
(n = 1098)
Records excluded
(n = 1037)
Full-text articles assessed
for eligibility
(n = 61)
Studies included in
qualitative synthesis
(n = 7)
Studies included in
quantitative synthesis
(meta-analysis)
(n = 0)
 Full-text articles excluded,
 with reasons (n = 54)
- Spinal/Pelvis only (n = 39)
- Case report < 5 eligible patients (n = 7)
- Review article (n = 2)
- Incomplete outcome data (n = 4)
- Short descriptive (n = 1)
- Lack of control group (n = 1)
Fig. 1 Search process.
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Jernigan et al35) compared preoperative embolization to a 
control group not receiving preoperative embolization. 
The other three studies (Chatziioannou et  al,29 Kickuth 
et al,30 and Sun et al34) made a distinction of technically 
successful embolizations (defined as more than 70% 
reduction of arterial blush) to incomplete embolizations 
and measured intraoperative blood loss.
The retrospective study by Pazionis et al found a signifi-
cant reduction of perioperative blood loss and reduced 
need for blood transfusion following preoperative embo-
lization. Their study included 27 patients with renal cell 
carcinoma and 12 patients with thyroid carcinoma, who 
all underwent embolization before surgery. Their control 
group consisted of 41 patients, also undergoing surgery, 
who did not have embolization and who were matched 
based on potential hypervascularity (i.e. underlying histo-
logic diagnosis and lytic radiographic pattern), tumour 
size and operation type. If no appropriate control patient 
with renal cell or thyroid metastases could be found, 
patients with multiple myeloma were used and added to 
the control group (n = 6). Blood loss was 900±1230 mL in 
the group that underwent embolization versus 1770±2590 
mL in the control group. The transfusion rate was 
2.15±3.03 units in the group that underwent emboliza-
tion versus 3.56±5.37 units in the control group.32
The retrospective study by Ratasvuori et  al found no 
significant reduction in perioperative blood loss for 
patients who underwent preoperative embolization. Their 
study included 144 patients who all underwent surgery of 
bone metastases from renal cell carcinoma, 56 of these 
patients underwent preoperative embolization. There was 
no strict protocol for when to use embolization. Baseline 
characteristics of both groups were similar regarding age, 
mean tumour size and localization. Metastases were 
found in the femur (n = 82), humerus (n = 37), pelvis (n = 
15) and other localizations (n = 14). Average perioperative 
blood loss was 1100 mL (range 5–5700 mL) and 1000 mL 
(range 5–12000 mL) for, respectively, the group that 
underwent preoperative embolization versus the control 
group.33 Also the retrospective study by Jernigan et al did 
Table 3. Included studies
Author, year Study 
design
Primary tumour Location 
metastasis (n)
Inclusions 
(n)
embolizations 
(n)
Control Primary 
outcome
Oxford levels 
of evidence
MINORS 
score
Sun et al, 
199834
Case-
cohort
Renal cell carcinoma Femur (11)
Pelvis (1)
Humerus (1)
Spinal (2)
16 16 Complete 
devascularization 
vs incomplete 
devascularization
Blood loss 3 11
Chatziioannou 
et al, 200029
Case-
cohort
Renal cell carcinoma Femoral/
acetabular region
(17)
Humerus (9)
Pubic ramus (1)
Scapula (1)
26 28* Complete 
devascularization 
vs incomplete 
devascularization
Blood loss
Transfusion 
requirements
3 11
Kickuth et al, 
200830
Case-
cohort
Multiple:
renal cell carcinoma 
(18), malignant 
melanoma (1), 
leiomyosarcoma 
(1), hepatocellular 
carcinoma (1), 
prostate carcinoma (1)
Femur (14)
Humerus (4) 
Acetabulum (1)
Tibia (1)
Ulna (1)
L2 vertebral body 
(1)
22 22 Complete 
devascularization 
vs incomplete 
devascularization
Blood loss 3 7
Pazionis et al, 
201432
Case-
cohort
Renal cell carcinoma 
and thyroid carcinoma
Femur (49)
Humerus (35)
Pelvis (31)
Scapula (7)
118** 53 Preoperative 
embolization 
vs operative 
treatment only
Blood loss
Operation time
renal function 
impairment
3 13
Kim et al, 
201531
Case-
cohort
Hepatocellular 
carcinoma
Femur (36)
Humerus (22)
Pelvis (9)
Pelvis and 
proximal
femur (3)
Other sites (5)
75 22 Preoperative 
embolization 
vs operative 
treatment only
Blood loss
Clinical 
outcomes 
(haemoglobin 
levels, admission 
length, no 
transfusions)
3 9
Ratasvuori 
et al, 201633
Case-
cohort
Renal cell carcinoma Femur (82)
Pelvis (15)
Humerus (37)
Other (14)
148 56 Preoperative 
embolization 
vs operative 
treatment only
Blood loss 3 13
Jernigan et al, 
201835
Case-
cohort
Renal cell carcinoma Femur 1285 135 Preoperative 
embolization 
vs operative 
treatment only
Transfusion 
requirements
3 12
Note. MINORS, Methodological Index for Non-Randomized Studies.
*Two patients were embolized twice in the same area due to relapse after the first operation.
**Two patients underwent two separate preoperative transcatheter arterial embolization sessions, four patients underwent embolization of two sites in the same 
session.
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not find a reduction in the postoperative blood transfu-
sion requirements of patients who underwent preopera-
tive embolization. They reviewed patients who underwent 
prophylactic femoral surgery for renal cell carcinoma, and 
compared 135 patients who underwent preoperative 
embolization to 1150 patients who did not. Data were 
retrieved from a large healthcare database. No difference 
in transfusion requirements was observed between pre-
operative transarterial embolization (41 of 135, 30%) and 
the control group (359 of 1150, 31%). The group that 
underwent preoperative embolization was more likely to 
be < 75 years old compared to the control group, and no 
protocol to determine which patients were eligible for 
preoperative embolization, nor the exact number of blood 
transfusions that were required could be retrieved from 
this retrospective database study.35
Of the three studies that made a distinction between 
successful and unsuccessful embolization, Sun et al and 
Chatziioannou et al both found a reduction in intraopera-
tive blood loss, whereas Kickuth et al did not find a reduc-
tion. Sun et al retrospectively reviewed 16 patients with 
metastases of the femur (n = 11), humerus (n = 2), spine 
(n  = 2) and ischium (n = 1). A successful embolization 
(defined as obliteration of more than 70% of the tumour 
stain) was achieved in 12 patients and led to a significant 
reduction of intraoperative blood loss (460 mL versus 
750  mL).34 Chatziioannou et  al retrospectively reviewed 
26 patients with metastases of the femur/acetabular 
region (n = 17), humerus (n = 9), pubic ramus (n = 1) and 
scapula (n = 1). A complete embolization was achieved in 
10 patients, and embolization was incomplete in the 
remaining 16 patients. Complete embolization resulted in 
a significant reduction of intraoperative blood loss 
(535±390 mL versus 1247±1047 mL) and red blood cell 
transfusion (1.3 units versus 2.4 units).29 Kickuth et  al, 
however, did not find a significant reduction in intraoper-
ative blood loss. They retrospectively reviewed 22 patients, 
18 of whom had metastases of renal cell carcinoma. They 
grouped their patients according to the success of preop-
erative embolization: Group I, > 75% reduction of tumour 
blush; Group II, 50–75% reduction of tumour blush; and 
Group III, less than 50% reduction of tumour blush. 
Metastases were mainly found in the femur (n = 14), and 
humerus (n = 4). The median intraoperative blood loss of 
Group I was 500 mL (n = 13, 200–4000 mL), of group II 
was 1475 mL (n = 8, 350–3800 mL) and of group III was 
2500 mL (n = 1), but these differences were not found to 
be significant.30 In conclusion, three out of six level III evi-
dence studies showed a reduction in perioperative blood 
loss and/or blood transfusion requirement after preopera-
tive embolization of renal cell carcinoma metastases in 
long bones, three out of six studies did not.
Blood loss in metastasis of hepatocellular carcinoma
There is one study, by Kim et al,31 that describes preop-
erative embolization of metastases of hepatocellular car-
cinoma. This retrospective case series provides some 
indirect evidence to support preoperative embolization. 
The case series included 22 patients who underwent pre-
operative embolization and 53 patients who underwent 
operative treatment without preoperative embolization. 
Seven patients were excluded because preoperative 
Table 4. Primary outcome measure
Author, year Tumour (n*) Effect
Sun et al, 199834 RCC (16) Less blood loss after successful embolization:
- Successful embolization/unsuccessful embolization: 460 mL / 750 mL
Chatziioannou et al, 200029 RCC (28) Less blood loss after complete embolization:
- Complete embolization/incomplete embolization: 535±390 mL / 1247±1047 mL
Less red blood cell transfusion after complete embolization:
- Complete embolization/incomplete embolization: 1.3 units/2.4 units
Pazionis et al, 201432 RCC (37)/TC (12) Less blood loss after embolization:
- Embolization/control: 900±1230 mL / 1770±2590 mL
Less transfusion volume after embolization
- Embolization/control: 2.15±3.03 units /.3.56±5.37 units
- Shorter operation time
- Embolization/control: 3.13 hours/3.91 hours
Kim et al, 201531 HCC (22) No difference in blood loss or transfusion need after embolization.
Reduced postoperative haemoglobin drop:
Embolization: day 0: 0.82 mg/dL, day 2: 1.03 mg/dL
Control: day 0: 1.94 mg/dL, day2: 2.23 mg/dL
Kickuth et al, 200830 RCC (18) and mixed tumours (4) No significant decrease in blood loss according to embolization success
- > 75% embolization success: blood loss 500 mL (200–4000mL, n = 13)
- 50–75% embolization success: blood loss 1475 mL (350–3800mL, n = 8)
- < 50% embolization success: blood loss 2500 mL (n = 1)
Ratasvuori et al, 201633 RCC (56) No effect on blood loss after embolization
- Embolization/control: 1100mL (range 5–5700mL) / 1000 mL (range 5–12000 mL)
Jernigan et al, 201835 RCC (135) No effect on transfusion requirements
- Embolization/control: 41 of 135 (30%) / 359 of 1150 (31%)
Note. RCC, renal cell carcinoma; HCC, hepatocellular carcinoma; TC, thyroid carcinoma.
*Number of patients with embolization.
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embolization was unsuccessful. The remaining groups 
were similar, except that the occurrence of pelvic metasta-
ses was significantly higher in the group that underwent 
embolization. There was no significant difference in our 
primary outcome measures: perioperative blood loss 
(2527 mL versus 2002 mL, p = 0.373) or red blood cell 
transfusion (7.55 units versus 4.58 units, p = 0.101). How-
ever, the haemoglobin drop on postoperative day zero 
and day two was significantly reduced (0.82 mg/dL versus 
1.94 mg/dL on day 0, and 1.03 mg/dL versus 2.23 mg/dL 
on day 2). Location of the surgically treated metastases 
included mainly femur (n = 36), humerus (n = 22), and 
pelvis (n = 9), and most surgical procedures consisted of 
an internal fixation (n = 49) or en bloc excision and tumour 
prosthesis reconstruction (n = 19).
Blood loss in metastasis of thyroid carcinoma
We did not find evidence to support preoperative emboli-
zation of thyroid tumour metastases in long bones. The 
study by Pazionis et al reported on preoperative emboliza-
tion of thyroid carcinoma. This study retrospectively com-
pared a group of patients who underwent preoperative 
embolization versus a group that did not undergo preop-
erative embolization, but both groups predominantly 
included patients with metastases of renal cell carcinoma. 
This study showed a significant reduction of perioperative 
blood loss following embolization; however, because a 
subgroup analysis of thyroid carcinoma metastases is 
missing we cannot draw conclusions.32
Blood loss in metastasis of other primary tumours
We did not identify studies that described the effects of 
preoperative embolization of metastases of other primary 
tumours such as metastases of mamma carcinoma, lung 
carcinoma or prostate carcinoma. Therefore there is no 
evidence available to support preoperative embolization 
of metastases of other primary tumours.
Secondary outcome measures
Operation time
Whether preoperative embolization will lead to a reduc-
tion of operation time cannot be proven based on the lit-
erature we analysed. Pazionis et  al concluded that the 
operation time of patients who underwent preoperative 
embolization was significantly reduced (3.13 hours versus 
3.91 hours).32 Ratasvuori et al, however, were unable to 
show that embolization resulted in a significantly shorter 
operation time. They found a mean operation time of 157 
min (65–420 min) in the group that underwent preopera-
tive embolization versus 120 min (45–420 min) in the 
control group. In a subgroup analysis of patients with 
humerus metastases of renal cell carcinomas (n = 37) they 
even showed that operation time was significantly shorter 
for patients who did not undergo embolization (n = 23).33 
Kim et al also showed that operation time was significantly 
longer in the group that underwent preoperative emboli-
zation (263±124 min versus 197±73 min).31
Effectiveness and complications of embolization
Effective embolization of bone metastases is often defined 
as a reduction of > 70% of the vascularization. Four stud-
ies reported their success rates ranging from 36% to 
80%.30–32,34
Embolization-related complications were reported in 
all included studies except the studies by Chatziioannou 
et al and Jernigan et al.29,35 The incidence of complications 
varies between 0% and 9%. Five of the included studies 
reported their complication rates. Three major embolization- 
related complications were reported in a total of 169 per-
formed procedures. Kickuth et al reported both a transient 
sciatic palsy and a gluteal abscess after embolization that 
required surgical debridement.30 Kim et al reported a rup-
tured vessel, which had to be embolized.31 Embolization 
did not affect renal function in patients with a normal pre-
operative renal function.32 Postembolization syndrome, 
which presents with symptoms such as fever, pain and 
malaise, is a commonly described side effect, but gener-
ally resolves completely within five days of symptomatic 
therapy. Sun et al reported that three of their 13 embo-
lized patients were showing signs of postembolization 
syndrome.34
Timing of embolization
The included studies performed surgery within 48 hours30 
or 72 hours29,33,34 after embolization. Whether the interval 
between embolization and surgery influences outcome 
remains unclear. Sun et al found no significant difference 
between patients who underwent surgery within 24 
hours of embolization compared to those who had sur-
gery after more than 36 hours (575 mL versus 402 mL).34
Discussion
Preoperative embolization of bone tumours was intro-
duced by Feldman et al in 1975.36 Following this report, 
the hypothesis that preoperative embolization of metasta-
ses reduces intraoperative blood loss was postulated by 
some authors during the 80s and 90s.17–19 This led to the 
belief that preoperative embolization is an effective way of 
reducing perioperative blood loss with surgical treatment 
of long bone metastases. The aim of this systematic review 
was to analyse all available literature regarding the effec-
tiveness of preoperative embolization of long bone metas-
tases to reduce blood loss during surgical treatment of 
(impending) pathological fractures.
Based on this systematic literature review limited evi-
dence is found to support embolization for renal cell car-
cinoma bone metastases. However, this is based on 
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low-quality studies, retrospective, non-randomized case 
control series with variable outcomes. There is some 
indirect evidence from a low-level study that can sup-
port preoperative embolization of bone metastases of 
hepatocellular carcinoma. We could not find evidence 
that supports embolization of bone metastasis of thyroid 
carcinoma and metastases of other origin. Although the 
evidence regarding the effectiveness of preoperative 
embolization for renal cell carcinoma is not unambigu-
ous, three out of six studies showed a positive effect. Fur-
thermore, the study by Ratasvouri et al correlated a less 
successful embolization with more perioperative blood 
loss. So half of the studies included in this review showed 
a decrease in perioperative blood loss or transfusion 
requirement after preoperative embolization of renal cell 
carcinoma, with reductions ranging between 290 and 
1000 mL, and 1.1–1.4 units of blood transfusion required. 
Despite the fact that this evidence mainly comes from ret-
rospective level III studies, it seems reasonable to con-
clude that preoperative embolization of metastases of 
renal cell carcinoma leads to a reduction in blood loss. To 
draw conclusions about whether bone metastases of 
hepatocellular carcinoma and thyroid carcinoma benefit 
from preoperative embolization is more difficult. Only one 
study showed some indirect effect (smaller haemoglobin 
drop after surgery) of embolization of metastases of hepa-
tocellular carcinoma; however, this was not reflected in 
our primary outcome measurements (perioperative blood 
loss or transfusion requirement).
The aim of this review was to determine the effective-
ness of all types of bone metastases, including other com-
monly seen metastases originating from lung, breast, or 
prostate tumours. Despite our general search, there data 
were only found on metastases of renal cell carcinoma, 
hepatocellular carcinoma, and thyroid carcinoma. Whether 
metastases of other primary tumours could benefit from 
preoperative embolization is therefore uncertain. Some 
authors have argued that all metastases are by definition 
hypervascular, with some being extremely hypervascu-
lar.37 Hypervascularity could be assessed through obtain-
ing a preoperative magnetic resonance imaging (MRI) 
scan or contrast-enhanced computed tomography (CT) 
scan. At MRI, signs of contrast enhancement, presence of 
large-flow voids, intratumoural haemorrhage, all predict 
tumour hypervascularity. However, the lack of these crite-
ria does not exclude hypervascular metastases.38 The 
accuracy of contrast-enhanced CT for detecting hypervas-
cular bone tumours is unknown, but its sensitivity and 
specificity to detect hypervascular liver metastases in soft 
tissues are respectively 97% and 76%.39 Furthermore, 
large case series such as those described by Ristevski et al,8 
including more than 600 patients undergoing stabiliza-
tion of metastatic femur lesions, or national databases 
including patients with surgically treated bone metastases, 
such as the Dutch OPTIMAL cohort40 would help to pro-
vide data on perioperative blood loss, specified per 
tumour, in order to identify other metastatic tumours that 
might benefit from preoperative embolization.
It remains difficult to determine the effect of preopera-
tive embolization for surgically treated bone metastases 
because (1) the type of primary tumour, (2) the location, 
and (3), the type of surgery, may all influence the amount 
of perioperative blood loss. Within the present literature, 
these factors are generally combined into one research 
group and compared to a matched untreated group. This 
inevitably leads to a wide range of reported blood loss, 
making detection of significant differences more challeng-
ing. However, more importantly, the outcome of these 
studies cannot answer the question of whether metasta-
ses that need specific surgical treatment need to be embo-
lized. A recently published meta-analysis on preoperative 
embolization of metastases in spinal surgery struggles 
with the same issue.41 Although the meta-analysis con-
cludes that it is effective to embolize spinal metastases, no 
specified recommendation can be made per surgical tech-
nique, because the included techniques range from exten-
sive open surgery such as complete vertebrectomy and 
anterior fixation, to minimally invasive surgery such as 
dorsal spondylodesis. Because many patient and disease 
factors are combined within research populations, it is dif-
ficult to compare outcomes between studies. From a surgi-
cal point of view, randomized studies taking into account 
the three major factors determining perioperative blood 
loss (type of primary tumour, location of metastases, type 
of surgery) are therefore desired.
Conclusions
The clinical level of evidence that supports the effective-
ness of preoperative embolization in order to reduce peri-
operative blood loss during surgical treatment of long 
bone metastases is low. Three retrospective case-cohort 
studies show that embolization of metastases originating 
from renal cell carcinoma reduced perioperative blood 
loss and/or blood transfusion requirements. One study 
shows that embolization of hepatocellular carcinoma 
metastases reduced postoperative haemoglobin drop, 
but does not reduce perioperative blood loss and/or 
transfusion requirement. For metastases of other primary 
tumours, no clinical evidence is available to make further 
recommendations. Preoperative embolization is techni-
cally successful in 36–75% of cases and is associated 
with complications in up to 9%. Surgery after emboliza-
tion is always performed within 72 hours. More rand-
omized controlled studies taking into account (1) 
primary tumour type (e.g. renal cell carcinoma, thyroid 
carcinoma, mamma carcinoma or lung carcinoma), (2) 
location (e.g. femur, humerus, pelvis), (3) and surgical 
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technique (e.g. intramedullary nailing, plating or arthro-
plasty), are needed to develop more detailed recommen-
dations about which long bone metastases should 
undergo preoperative embolization.
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